|Dr. Brian Lian||Pres, CEO & Director||752k||N/A||1966|
|Mr. Michael Morneau||VP of Fin. & Admin.||375.33k||N/A||1965|
|Mr. Gregory S. Zante||Sr. VP of Fin.||N/A||N/A||1971|
|Ms. Amy Broidrick||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
|Ms. Marianne Mancini||Sr. VP of Clinical Operations||N/A||N/A||N/A|
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase II clinical trials to treat patients with non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in preclinical stage for X-linked adrenoleukodystrophy. The company was founded in 2012 and is headquartered in San Diego, California.
Viking Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 9. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 8.